There have been many ASX shares that have delivered their latest numbers to investors so far this earnings season. Some have been impressive, others middling. But one report turned my head faster than any other. That would be the earnings from ASX tech stock and dividend share Pro Medicus Ltd (ASX: PME).
The medical imaging software company posted its earnings for the full 20206 financial year on Tuesday of this week.
As we covered at the time, there wasn’t much to turn one’s nose up at. Pro Medicus announced that its revenue for the 12 months to 30 June 2026 came in at $261.7 million, up a whopping 22.9% year on year.
Meanwhile, underlying earnings before interest and tax rose 24.4% to $$16.1 million. That helped to increase the company’s underlying net profits after tax (NPAT) by 24.1% to $144.7 million.
On the bottom line, Pro Medicus reported a statutory NPAT of $265.3 million, up 130.3%.
Those metrics are all well and good, pointing to a company whose growth engine is firing on all cylinders. But it was the dividend that Pro Medicus revealed that really drew my eye.
A massive pay rise from a stellar ASX dividend share
Pro Medicus unveiled a final dividend of 37 cents per share for FY2026. That alone represents a 23.33% hike over the final dividend of 30 cents per share from 2025.
Together with the interim dividend of 32 cents per share from March, it takes Pro Medicus’ 2026 payouts to 69 cents per share. That’s a 25.45% increase over 2025’s total of 55 cents per share.
As is this ASX dividend’s habit, all of those dividends came with full franking credits attached.
If this ascension from 55 to 69 cents per share for Pro Medicus’ payouts was a one-off, that would be one thing. However, this latest increase is just the latest in a long line of dramatic payout rises from this ASX dividend share.
Pro Medicus delivered a dividend hike almost every year of the past 15 years. The last time investors saw a cut was back in 2011. Since 2018, this stock has gone from paying out 6 cents a share to 2026’s 69 cents. That’s a compounded annual growth rate of 35.7%. Wealth-making stuff.
This incredible trajectory exemplifies why I’ve always wanted to own this ASX dividend share. Hopefully, I’ll get my chance before the next dramatic dividend hike.
The post This ASX dividend share just blew me away appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Healthcare results wrap: Are Cogstate and Pro Medicus shares a buy, hold or sell?
- Here are the top 10 ASX 200 shares today
- Why are Pro Medicus shares surging more than 10%?
- Why is everyone talking about CSL, Pro Medicus and BHP shares on Tuesday?
- Pro Medicus FY26: Strong earnings growth and higher dividend
Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.